By contrast, other authors reported a higher rate of RPILD in anti-Ro52+ patients with ARS [38], while in juvenile DM, anti-Ro52 is a predictive factor of non-remission due to active associated-ILD [39]. The gene discussed is TRIM21; the disease is juvenile dermatomyositis.